Charah Solns: Q2 Earnings Insights

  Charah Solns (NYSE:CHRA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

 

Charah Solns (NYSE:CHRA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

Charah Solns missed estimated earnings by 61.9%, reporting an EPS of $-0.34 versus an estimate of $-0.21.

Revenue was up $13.59 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.23 which was followed by a 18.13% drop in the share price the next day.

Here’s a look at Charah Solns’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.19 0.06   -0.1
EPS Actual -0.42 -0.02 -0.08 -0.2
Revenue Estimate 66.07M 84.11M 77.20M 74.50M
Revenue Actual 66.05M 93.43M 84.16M 63.52M

To track all earnings releases for Charah Solns visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss

Cannara Biotech Inc. announced on Monday its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024. The company reported a 68% year-over-year increase in revenues for the first half of fiscal 2024, a metrics CFO Nicholas Sosiak called "a testament to our growing influence in the Quebec, Ontario, Alberta, and BC markets." "Our proactive steps towards streamlining assets align with our ambition to fortify our financial foundation as we relentlessly stay focused on gaining market share and becoming the leader in Canada, the second-largest cannabis market in the world," Sosiak said. "As for our long-term vision, we do see our future extend beyond our borders where Cannara is a globally recognized brand synonymous with excellence and value in cannabis."

LOVE